Latest News
06-22-17 Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome 05-31-17 Zogenix to Present at the Jefferies 2017 Global Healthcare Conference 05-22-17 Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry more »Spotlight on Clinical Studies
The Zogenix study entitled "A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome" is being conducted for patients with Dravet syndrome who are not adequately controlled on their current seizure medication. For more information, please visit www.clinicaltrials.gov listing (NCT02682927).
more »Scientific Publications
- An Examination of the Mechanism of Action of Fenfluramine in Dravet Syndrome: A Look Beyond Serotonin
- Updated data presented at the 70th Annual American Epilepsy Society Meeting
- Evolution of Low-Dose Fenfluramine in the Treatment of Epileptic Encephalopathies: New Understandings of the Mechanisms, Basic Science, and Clinical Data